LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LTB Infection Estimated with Interferon-γ Release Assay

By LabMedica International staff writers
Posted on 01 Nov 2018
Print article
Image: The T-SPOT.TB test is a unique, single-visit blood test for tuberculosis (TB) screening, also known as an interferon gamma release assay (IGRA) (Photo courtesy of Oxford Immunotec).
Image: The T-SPOT.TB test is a unique, single-visit blood test for tuberculosis (TB) screening, also known as an interferon gamma release assay (IGRA) (Photo courtesy of Oxford Immunotec).
Latent tuberculosis (LTB), also called latent tuberculosis infection (LTBI) is when a person is infected with Mycobacterium tuberculosis, but do not have active tuberculosis. Active tuberculosis can be contagious while latent tuberculosis is not, and it is therefore not possible to get infected from someone with latent tuberculosis.

In Japan, university students, including foreign-born students, undergo TB screening with chest radiograph; however, a chest radiograph cannot detect LTBI; it detects only pulmonary TB. Because immigrants may develop TB after entry, screening with chest radiograph might be ineffective; therefore, screening for LTBI may be necessary to prevent TB outbreaks.

Scientists at Keio University School of Medicine (Tokyo, Japan) and their colleagues enrolled 177 participants 20–42 years of age (median 23 years), of whom 98 (55.1%) were female. Participants were from China (55 students), Indonesia (24 students), France (19 students), Germany (nine students), and Thailand (eight students); the remaining participants were from 28 different countries; including 50 from countries with estimated TB incidence rates greater than 100 cases/100,000 persons.

The team collected whole blood specimens for the T-SPOT.TB test, an Interferon-γ Release Assay (IGRA) available in Japan. All participants were screened for pulmonary TB with chest radiograph. They interviewed participants using a structured questionnaire on identification and demographic information, the date of first arrival in Japan, and history of TB.

The scientists found that overall, eight (4.5%) students tested positive on IGRA (two each from China and Thailand and one each from Ghana, Indonesia, South Korea, and the Philippines). The rate of the positive IGRA result for students from countries with an estimated TB incidence rate of >100 cases/100,000 persons was 10.0% and relative risk was 4.2, whereas the rate for students from countries with an estimated TB incidence rate of <100 cases/100,000 persons was 2.4%. The IGRA positivity of students 20–29 years of age from countries with estimated TB incidence rates of >100 cases/100,000 persons was 9.4%.

The authors concluded that estimated LTBI rates for foreign-born students in Japan from countries with high TB incidence rates were higher than those for students from countries with low TB incidence rates and for students from Japan. Based on their findings, they recommend that universities screen for LTBI using IGRAs in students from countries with high TB incidence rates (i.e., >100 cases/100,000 persons). The study was published in the November 2018 issue of the journal Emerging Infectious Diseases.

Related Links:
Keio University School of Medicine

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.